You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀下調信達生物(01801.HK)目標價至65元 評級「買入」
阿思達克 01-25 09:52
瑞銀髮表研究報告指,看好信達生物(01801.HK)綜合研發、商業化和執行能力,維持「買入」評級。 報告指出,最新版國家醫保藥品目錄年初起實施,隨着目錄中的PD-1新價格公佈後,認爲市場對信達生物的主要擔憂仍是PD-1用於治療非鱗狀非小細胞肺癌的美國生物製劑申請許可何時會獲批。 瑞銀將信達生物境外PD-1獲批成功率預期,由100%降至75%,以反映合作夥伴禮來近期對信迪利單抗(Tyvyt)的FDA申請看法變得更爲保守。但瑞銀表示,依然看好信達在所有臨牀階段的穩固產品線,預期可持續推動增長。信達生物的股價去年中以來累跌50%,瑞銀認爲其長期潛力並未被完全反映。 該行將信達2021至2023年每股虧損預測下調至1.18、0.95及0.13元人民幣,調整風險後峯值銷售額預期由230億上調至260億元人民幣,目標價121.2元下調至65元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account